22nd Century Group (XXII) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
The company has undergone a significant turnaround over the past 11 months, focusing on operational improvements, cost reductions, and a simplified business model, now structured into contract manufacturing (CMO) and branded product (VLN) segments.
Net revenues for Q3 2024 were $5.95M, down 24.5% year-over-year, with a net loss from continuing operations of $3.59M and a basic and diluted loss per share of $0.27, a significant improvement from the prior year.
Management is targeting EBITDA breakeven by Q1 2025, leveraging CMO customer relationships and expanding VLN distribution, including private-label and new SKUs.
Cash and cash equivalents stood at $5.34M as of September 30, 2024, with working capital improved to $1.57M from a deficit of $6.83M at year-end 2023.
Substantial doubt remains about the company's ability to continue as a going concern due to ongoing losses and negative cash flows.
Financial highlights
Q3 2024 net revenue was $5.95M, down from $7.9M in Q2 2024 and down 24.5% year-over-year, primarily due to lower shipment volumes.
Gross margin for Q3 2024 was negative at -9.9%, with gross profit turning negative at $(0.6)M compared to $0.6M previously.
Operating expenses for Q3 2024 were $2.79M, down 66.5% from $8.33M in Q3 2023 due to cost cuts and restructuring.
Net loss from continuing operations for Q3 2024 was $3.59M, with EPS at $(0.27), a substantial improvement from $8.08M loss and $6.70 per share in Q3 2023.
Net debt reduced to $3.0M from $13.3M at the start of the year, and shareholders' equity improved by nearly $12M year-to-date.
Outlook and guidance
Management is targeting EBITDA breakeven in Q1 2025, with expectations of revenue growth and improved margins from core CMO business.
Q4 2024 revenues are expected to be consistent with Q3, with less filtered cigar volume but new export volume ramping up.
Anticipates increasing volume in 2025 across all product lines, driven by new and expanded contracts, including VLN.
Expects increased spending in 2025 for sales and marketing to support VLN and flanker brand launches.
Management is evaluating further expense reductions and financing strategies, including securities issuance, asset sales, and strategic partnerships.
Latest events from 22nd Century Group
- Revenue grew, losses narrowed, but going concern risk persists as VLN rebranding continues.XXII
Q2 20241 Feb 2026 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Key votes include a reverse split, preferred stock, warrant changes, and a new offering.XXII
Proxy Filing30 Dec 2025 - VLN relaunch, FDA compliance, and CMO focus drive 2025 growth after 2024 turnaround.XXII
Q4 202426 Dec 2025 - Relaunching low-nicotine brands, expanding retail reach, and targeting profitability by Q4 2025.XXII
Emerging Growth Conference26 Dec 2025 - Special meeting seeks approval for reverse split, anti-dilution terms, and new capital offering.XXII
Proxy Filing19 Dec 2025 - Resale of 1.4M shares enables debt settlement for a tobacco innovator with FDA-authorized VLN products.XXII
Registration Filing16 Dec 2025 - Registering 104,124 shares for resale, with no proceeds to the company and ongoing financial risks.XXII
Registration Filing16 Dec 2025 - Registering 93.6M shares for resale; proceeds only from warrant exercises; faces losses and regulatory risks.XXII
Registration Filing16 Dec 2025